Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human type XVII collagen microneedle
- Development stage
- Unknown
- Lead developer
- Shanghai Children's Medical Center
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal, Percutaneous
01
Overview
Recombinant human type XVII collagen microneedle is a drug-device combination product designed for the treatment of refractory burn wounds. It utilizes recombinant human type XVII collagen (rhCOL17), a key structural protein of the hemidesmosome that maintains the connection between the epidermis and dermis. By delivering this protein directly into the skin via a microneedle array, the treatment aims to accelerate re-epithelialization and improve healing outcomes in non-healing or pediatric burn wounds. The product is currently being evaluated in clinical trials at the Shanghai Children's Medical Center.
- Other names
- recombinant human collagen microneedlesrhCOL17 microneedlerhCOL-17 microneedlerhCOL 17 microneedle
02
Targets
COL1A1 (Collagen type I alpha 1 chain)
Beyond the preview
Go deeper on recombinant human type XVII collagen microneedle.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human type XVII collagen microneedle.